Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing saidvector and manufacturing method of products which is produced from said microorganism
CA 2072375 C · Owner: Japan Energy Corporation · Inventors: Furuya, Hideyuki; Matsuda, Hitoshi; Inoue, Yoshifumi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided is a chimeric HV1/HV3 hirudin analog useful as an anti-coagulant, exhibiting higher anti-thrombin activity and less tendency to cause bleeding than hirudin HV1. Also provided are a method of producing hirudins and hirudin analogs as well as other proteins, employing secretion vectors and transformed microorganisms such as E. coli. Pharmaceutical compositions comprising various hirudins or the chimeric HV1/HV3 hirudin analog of the present invention and a pharmaceutically acceptable carrier are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 8, 1991 and granted January 11, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 8, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 8, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.